논문검색
Author Shin Myung Kang, Moo Suk Park, Joon Chang, Se Kyu Kim, Haeryoung Kim, Dong Hwan Shin, Kyung Young Chung, Dae Joon Kim, Joo Hyuk Sohn, Sung Ho Choi, Jeongmi Kim, Eun Jin Yoon, Joo Hang Kim
Place of duty Departments of 1Internal Medicine, 2Pathology, 3Cardiovascular and Thoracic Surgery, 4Yonsei Cancer Center, Yonsei University College of Medicine, 5ISU ABXIS CO., LTD, Seoul, Korea.
Title A Feasibility Study of Adenosine Triphosphate-based Chemotherapy Response Assay (ATP-CRA) as a Chemosensitivity Test for Lung Cance
Publicationinfo Cancer Res Treat. 2005 Aug; 037(04): 223-227.
Key_word Chemosensitivity test,ATP-CRA,Lung cancer
Full-Text
Abstract Purpose: A chemosensitivity test can reflect the differences in responses of individual cancer patients to chemotherapeutic agents. The adenosine triphosphate- based chemotherapy response assay (ATP-CRA)is an accurate method, which does not require a large amount of tissue specimen. So far, no studies have evaluated the utility of the ATP-CRA in Korea. Therefore, we investigated the clinical usefulness of the ATP-CRA in 53 patients with lung cancer. Materials and Methods: Tumor tissues were obtained from bronchoscopic biopsies or surgical resections. The validity of ATP-CRA was assessed focusing on the success rate, experimental error level (intraassay mean coefficient of variation [CV]) and reproducibility. Results: The overall success rate of ATP-CRA was 90.6% (48/53). Normal cells were effectively eliminatedfrom the tumor tissues with the use of ficoll gradient centrifugation and immunomagnetic separation, which was confirmed using loss of heterozygosity analysis of the 3p deletion. The mean CV of ATP assays was 10.5+/- 4.6%. The reproducibility of ATP assays was 94+/-3.8%. The results of the ATP assays were reported to physicians within 7 days of specimen collection. More than 6 anticancer drugs were tested on the tumor specimens obtained from bronchoscopic biopsies. Conclusion: The ATP-CRA is a stable, accurate and potentially practical chemosensitivity test in patients with lung cancer. (Cancer Res Treat. 2005;37:223-227)